JPWO2019217803A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019217803A5
JPWO2019217803A5 JP2021513376A JP2021513376A JPWO2019217803A5 JP WO2019217803 A5 JPWO2019217803 A5 JP WO2019217803A5 JP 2021513376 A JP2021513376 A JP 2021513376A JP 2021513376 A JP2021513376 A JP 2021513376A JP WO2019217803 A5 JPWO2019217803 A5 JP WO2019217803A5
Authority
JP
Japan
Prior art keywords
auxotrophic
donor template
vector
cells
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021513376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522865A (ja
JP2021522865A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031699 external-priority patent/WO2019217803A1/en
Publication of JP2021522865A publication Critical patent/JP2021522865A/ja
Publication of JP2021522865A5 publication Critical patent/JP2021522865A5/ja
Publication of JPWO2019217803A5 publication Critical patent/JPWO2019217803A5/ja
Withdrawn legal-status Critical Current

Links

JP2021513376A 2018-05-10 2019-05-10 栄養要求性調節可能な細胞を使用する遺伝子療法の方法および組成物 Withdrawn JP2021522865A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669848P 2018-05-10 2018-05-10
US62/669,848 2018-05-10
PCT/US2019/031699 WO2019217803A1 (en) 2018-05-10 2019-05-10 Gene therapy methods and compositions using auxotrophic regulatable cells

Publications (3)

Publication Number Publication Date
JP2021522865A JP2021522865A (ja) 2021-09-02
JP2021522865A5 JP2021522865A5 (https=) 2022-05-17
JPWO2019217803A5 true JPWO2019217803A5 (https=) 2022-05-17

Family

ID=66794093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513376A Withdrawn JP2021522865A (ja) 2018-05-10 2019-05-10 栄養要求性調節可能な細胞を使用する遺伝子療法の方法および組成物

Country Status (11)

Country Link
US (1) US20210052741A1 (https=)
EP (1) EP3790974A1 (https=)
JP (1) JP2021522865A (https=)
KR (1) KR20210030902A (https=)
CN (1) CN112513271A (https=)
AU (1) AU2019265916A1 (https=)
BR (1) BR112020022612A2 (https=)
CA (1) CA3098874A1 (https=)
MX (1) MX2020011757A (https=)
SG (1) SG11202010837XA (https=)
WO (1) WO2019217803A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230265440A1 (en) * 2020-06-26 2023-08-24 The Board Of Trustees Of The Leland Stanford Junior University Targeting the human ccr5 locus as a safe harbor for the expression of therapeutic proteins
WO2025080701A1 (en) * 2023-10-11 2025-04-17 William Marsh Rice University Genetically activated mesenchymal stem cells and stromal cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
CA2608913A1 (en) * 2005-05-18 2006-11-23 Biofactura, Inc. Compositions and methods for metabolic selection of transfected cells
US20090176260A1 (en) 2007-12-04 2009-07-09 Joseph Ching-Ming Wu Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
US20160122774A1 (en) 2013-05-29 2016-05-05 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
US11319555B2 (en) * 2014-11-20 2022-05-03 Duke University Compositions, systems and methods for cell therapy
GB201618414D0 (en) * 2016-11-01 2016-12-14 Patterson James Regulated cell lines and methods of use thereof

Similar Documents

Publication Publication Date Title
US9234211B2 (en) Hybrid promoter and recombinant vector comprising the same
JP7173548B2 (ja) 非組み込みウイルス送達系およびその関連方法
JP2022000470A (ja) 核酸製品及びその投与方法
EP1019499B1 (en) Methods and compositions for inducing tumor-specific cytotoxicity
US20220002364A1 (en) Rna encoding a protein
WO1994004695A1 (en) Herpesviral defective vector with rat preproenkephalin gene promoter
US20230295257A1 (en) Lipid nanoparticle comprising modified nucleotides
JP2015221026A (ja) 人工合成ｍＲＮＡの翻訳効率化方法
EP3420093B1 (en) Micelle based system nuclease encapsulation for in-vivo gene editing
JP2021522865A5 (https=)
KR102832420B1 (ko) 인공 합성 mRNA 및 그 이용
JPWO2019217803A5 (https=)
TW201735932A (zh) 使用微核醣核酸前驅物作爲誘導ｃｄ３４陽性成體幹細胞增殖之藥物
AU2021240417A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
CN100435848C (zh) 提高饲料效率和家畜生长速度的基因处理
KR20210030902A (ko) 영양요구 조절가능 세포를 사용한 유전자 요법 방법 및 조성물
EP2298896A1 (en) Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
RU2020140605A (ru) Способы и композиции для генной терапии с использованием ауксотрофных регулируемых клеток
WO2021209743A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
JP2022531930A (ja) 栄養要求性調節可能な細胞を使用する方法および組成物
EP4317434A1 (en) Rna delivery system for treatment of huntington's disease
TWI819203B (zh) 經修飾腺病毒及含有其之醫藥
KR20250076429A (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 운반체를 포함하는 대사성 질환 치료제
CN120442554A (zh) 一种含有TERT mRNA的外泌体及其制备方法和应用
Babu et al. Cancer gene therapies progress in pre and postgenomics era